# 1. Financial Performance ## A. Key Figures * **Group Revenue Growth:** **23%** YoY (Q2 & H1 FY26) * **Metropolis Organic Revenue:** **12%** Q2 FY26 · **12–13%** H1 FY26 * Metropolis EBITDA Margin: 26.8% (Q2 FY26) (+60 bps YoY) * MHL Organic Revenue Growth: 12% YoY · EBITDA: ₹104.8 Cr (+14.5%) · PAT: ₹53 Cr (+13.6%) * MHL EBITDA Margin: 26.8% (+210 bps QoQ, +60 bps YoY) · PAT Margin: 13.6% (+20 bps YoY) * MHL Group EBITDA Margin: 25.4% · PAT: ₹52.9 Cr · PAT Margin: 12.3% ## B. EBITDA & PAT Margins * **Core Diagnostics Profitability Inflection:** EBITDA margin improved to **high-single-digit** in Q2 from breakeven in March, signaling strong operational turnaround. * **Margin Divergence:** Group EBITDA margin at 4% reflects dilution from lower-margin Core Diagnostics, despite its sequential margin expansion from low- to higher-single-digit. * **Full-Year Margin Outlook:** Core Diagnostics expected to reach **double-digit EBITDA margins by year-end**, with full-year performance tracking to **strong single-digit** levels. ## C. Balance Sheet & Cash Flow * **CapEx-Driven Depreciation Increase:** Higher depreciation reflects recent asset additions, aligning with expansion and integration of Core. * **Lower Other Income Due to Acquisition:** Decline in investment income attributable to cash deployment for **Core acquisition in March**, reducing investable balances. --- # 2. Segment & Revenue Mix ## A. Key Figures * **B2C Revenue:** **59%** of total revenue, +11% YoY organic growth · **56%** Group-wide after acquisition consolidation * **TruHealth & Specialty Growth:** **+21%** and **+15%** YoY organic growth, respectively * **Acquired Entities Contribution:** **11%** of total revenue growth in Q2 ## B. B2C vs B2B Revenue * **Structural Shift to Organized Care:** Indian diagnostics market is consolidating around branded chains due to rising health awareness, quality focus, and cost pressures on unorganized labs, positioning Metropolis as a key beneficiary. * **B2C Strength with Stable Mix Outlook:** B2C remains dominant, driven by TruHealth and Specialty segments; mix may slightly favor B2C by year-end but no material margin impact expected. * **B2B Resurgence on Execution & Mix:** B2B revenue surged on strong volume growth and improved realizations, aided by a one-time clinical trial contract, with no escalation in price competition despite intense rivalry. * **Segment Reclassification Clarified:** Institutional business reclassified into B2B; recent shifts reflect mathematical reallocation, not underlying business change. ## C. TruHealth & Specialty Growth * **Premium & Rural Expansion via Bundling:** TruHealth and Specialty segments show robust double-digit growth, fueled by science-led test bundling, clinician engagement, and integrated care models. * **Radiology Integration Underway:** TruHealth now includes ECG (nationwide), X-ray, and ultrasound (5 towns), enhancing service depth; advanced imaging (MRI/CT) not planned for rollout this year. * **Radiology Revenue Still Immaterial:** Radiology contributes only a very low-single-digit percentage to total revenue and is not a current growth driver. ## D. Acquired Entities Contribution * **Acquisitions Accretive to Growth:** Three H1 acquisitions (Core Diagnostics, DAPIC, Scientific Pathology) contributed 11% to revenue growth, with integration on track and detailed performance to follow. * **Core Diagnostics Skews B2B Mix:** Consolidation of Core Diagnostics—predominantly B2B—explains lower B2C share at Group level versus MHL organic. --- # 3. Volume & Realization Trends ## A. Key Figures * Patient Volumes: 3.6 million MHL (+6%) · 3.7 million MHL Group (+11%) * Test Volumes: 7.4 Mn MHL (+6%) · 7.9 Mn MHL Group (+12%) * Revenue Growth: 22.7% YoY for MHL Group * **Volume Guidance:** **10–11%** consolidated growth expected for remainder of year ## B. Volume Drivers & Trends * **Resilient Growth Amid Seasonal Softness:** Fever-related test demand slowed due to lower disease incidence, yet volume momentum held firm through **strong uptake in Specialty and TruHealth testing**. * **Acquisition Lift:** Patient volume growth significantly supported by **Core Diagnostics integration**, contributing to double-digit group-level volume expansion. * **Clinical Trial Contribution:** Q2 volumes and revenue benefited from a clinical trial contract, though specific impact was not quantified. ## C. Realization & Pricing Dynamics * **Realization Run-Rate Clarified:** Near-doubling of lab charges in H1 primarily driven by **60% outsourcing costs linked to Core integration**, with management confirming **stable pricing trends** ahead. * **TruHealth RPP Expansion:** Average realization rising due to **enhanced test relevance, quality perception, and brand premium**, not genomic or ECG additions—though ECG has recently been included. * **Minimal Price Impact on Growth:** Only **2% of 12% organic growth** attributed to prior-year price hikes; **no new price increases planned** for FY26. --- # 4. Capacity & Network Expansion ## A. Key Figures * **Collection Centres Added:** **~200** in H1 FY26 · **300 planned** in H2 FY26 * **Geographic Reach:** Expansion to **750 towns** underway * **Lab-to-Centre Ratio:** Current **20–22 collection centres per lab** · Target of **30 per lab** in 12–18 months * **Tier 3 Revenue Contribution:** **24%** of total revenue * **Regional Revenue Mix:** **19%** from North region ## B. Collection Centre Growth * **Aggressive Network Buildout:** Robust expansion under *Metropolis 0* strategy, with **~500 new centres planned for FY26**, significantly broadening footprint in Tier 2 and Tier 3 cities. * **Franchise-Led Model:** Majority of new centres to be added via **franchisee route**, limiting P&L impact; only **top 5 or 6 cities** to see company-owned additions. * **Owned Network Scaling:** Owned service network has nearly doubled over three years, driven by **strategic urban expansion** and the addition of **over 100 labs**, each typically anchored by a new owned centre. ## C. Lab & Radiology Rollout * **Radiology Leverage:** Existing **35 centers across 5 cities** equipped with basic imaging capabilities will be used to scale radiology services, supported by **nationwide ECG rollout**. * **Procurement Tailwinds:** GST benefits on equipment to enhance procurement efficiency, improving capital deployment without direct P&L uplift. ## D. Tier 2/3 City Penetration * **Revenue Diversification:** Tier 3 towns now contribute **nearly a quarter of revenue**, reflecting successful rural and semi-urban penetration despite slower growth versus Tier 1. * **Regional Consolidation Trends:** **West and South markets** expected to consolidate faster due to higher health awareness, while **North and East face quality apathy** linked to lower education levels. * **Structural Barriers to Entry:** In **UP and Bihar**, new labs may proliferate due to access gaps, whereas **major cities see exit pressure** on small players from competition and compliance costs. --- # 5. Clinical Trials & Genomics ## A. Key Figures *No significant quantitative financial metrics available for extraction.* ## A. Trial Testing Performance * **Market Leadership in a Constrained Space:** Likely the largest or second-largest player in India’s turnkey clinical trial testing, serving MNC and domestic pharma with full regulatory compliance capabilities. * **Volume Momentum Building:** Recent operational improvements in partner portals and service efficiency driving expectations of higher trial volumes in coming quarters. ## B. Genomics & Oncology Platform * **Oncology-Focused Genomics Expansion:** Genomics strategy anchored in Core Diagnostics acquisition, targeting oncologists and hospital practices with advanced molecular and NGS capabilities. * **Preventive Genomics Not Viable in India:** Genetic testing excluded from preventive health packages due to lack of India-specific scientific validation for population-level predictions. ## C. R&D and Innovation Hub * **Digital & Automation Drive Efficiency:** New consumer and partner apps, auto-authorization middleware, and AI-based call monitoring enhancing TAT, scalability, and customer experience. * **AI: Near-Term Gains in Operations, Medical Applications Lagging:** Non-medical AI (e.g., billing, recruitment) delivering practical benefits within a year; medical AI remains theoretical due to unavailability of **Indian-specific datasets**. * **Innovation Infrastructure Scaling:** New Centre of Excellence in Delhi to accelerate R&D, test development, and scientific training in genomics and high-end diagnostics. --- # 6. Integration & Operational Risks ## A. Acquisition Clean-up Phase * **Integration on Track:** Acquisition integration progressing as planned, with stabilization, process alignment, and cost efficiencies underway across entities. * **Synergy Realization:** Synergies materializing as expected, supported by elimination of duplicate infrastructure and procurement savings, despite new technology and audit costs. * **Revenue Impact & Outlook:** Short-term revenue pressure from discontinuation of non-core practices; clean-up complete for B2B corporate/government businesses, setting foundation for **faster future growth** in Year 2. * **Core Diagnostics Status:** Technology, processes, and infrastructure largely integrated; people and cultural integration ongoing, with full completion expected in **a couple of more quarters**. * **Industry Consolidation Trend:** Low entry barriers have given way to high scaling challenges, leading to exits or slowdowns among small players; **organized sector gaining share** as technician-run and non-branded labs shut down. ## B. Pathologist Succession Risk * **Survival with Succession Gaps:** Pathologist-run independent labs maintain quality and remain viable, but face **looming closure risk** due to lack of next-gen interest in medical careers. --- # 7. Guidance & Outlook ## A. Key Figures * Organic Margin Expansion Guidance: 70–100 bps above prior year’s 24.3% · Group margin dilution of 1–1.2% due to Core operations * **Core Margin Progression:** **Q1: 2–3%** · **Q2: mid-to-high single digits** · **Q3: higher-single-digit (expected)** · **Q4: near double-digit (expected)**, averaging **high-single-digit for FY '26** ## B. Full-Year Revenue Guidance * **Guidance Maintained:** Company affirms full-year top-line guidance, supported by stable pricing and tailwinds from GLP-1 drugs and specialized testing. * **Near-Term Seasonality:** Q3 expected to be seasonally weakest due to festival slowdowns, though performance optimization remains a priority. * **FY27 Visibility Pending:** Management defers FY27 revenue outlook to next couple of quarters, citing need for further visibility despite ambition to elevate growth trajectory. ## C. Margin Expansion Targets * **Margin Drivers:** Focus on cost controls, automation, improved test mix, and productivity gains to drive targeted organic margin expansion. * **Non-Recurring Seasonal Boost:** Q2 margins benefited from seasonally high volumes; elevated levels not expected to continue into second half. * **Core Margin Trajectory:** On track to meet high-single-digit annual target, with progressive quarterly improvement expected through FY '26. ## D. FY27 Growth Trajectory * **Organic Scaling Focus:** No acquisitions planned for 6–9 months; strategic emphasis on operational efficiency, AI, and digitization to enable profitable, scalable growth. * **Growth Acceleration Pathway:** Revenue growth projected to reach **mid-teens** in FY27 and FY28, supported by expanded collection infrastructure and integration synergies. * **Long-Term Margin Roadmap:** Target to achieve current Metropolis margin levels in Core within 3 years post-acquisition, with **23–24%** margins feasible by **FY28**. * **Future Diagnostic Tailwinds:** Limited near-term impact from obesity/weight management testing, but management sees meaningful potential upon broader GLP-1 availability in India.